The present disclosure generally relates to the fields of genetics and diagnostic medicine. The invention more specifically relates to in vitro or ex vivo methods for assessing the cognitive function of a subject in the context of the prevention of neurodegenerative diseases. A particular method comprises a step of associating a subject to a cognitive status selected from healthy cognitive status, Subjective Cognitive Impairment, Mild Cognitive Impairment and neurodegenerative disease, wherein said association results from the evaluation of glycosylated MCSF and CCR2 expressed at the surface of PBMC in a biological sample from the subject. The present invention also provides kits suitable for implementing such methods.
